Rib-X reports positive Phase II results for antibiotic
This article was originally published in Scrip
Executive Summary
A Phase II trial of Rib-X Pharmaceuticals' radezolid showed the antibiotic was safe and effective for the treatment of community-acquired pneumonia (CAP).